期刊文献+

HPLC紫外检测法测定血浆甲磺酸瑞波西汀浓度 被引量:2

Determination of Reboxetine Mesilate in Plasma by High Performance Liquid Chromatography with Ultraviolet Detection
下载PDF
导出
摘要 目的建立测定血浆甲磺酸瑞波西汀浓度的高效液相色谱检测法。方法以麦普替林为内标,取血浆样本1mL,用饱和Na2HPO4碱化后以重蒸乙醚5mL提取,再用0.2mol.L-1盐酸0.2mL反提取,80℃~100℃热水浴下氮气吹干盐酸层,用50μL流动相重组后进样。采用InertsilODS-3柱(GLSciense,5μm,4.6mm×150mm)进行分离。流动相为乙腈-50mmol/L磷酸钠缓冲液(pH=6)(40:60,v/v),流速为0.6mL.min-1,紫外检测波长210nm。结果瑞波西汀对内标的峰高比与血浆甲磺酸瑞波西汀浓度直线相关,相关系数r=0.9997,线性范围3.12~200ng.mL-1。甲磺酸瑞波西汀的最低检测限0.5ng,最低检测浓度2ng.mL-1,提取回收率在82.50%~86.08%之间,批内和批间RSD分别为2.02%~5.33%和3.83%~8.50%。结论本法具有较高的灵敏度、精密度和特异性,适用于甲磺酸瑞波西汀的药代动力学和治疗药物监测的研究。 Objective To develop a method for the determination of reboxetine mesilate in plasma by high performance liquid chromatography. Methods With maprotiline hydroehloride as the internal standard, 1 mL plasma sample was extracted with 5 mL distilled diethyl ether and re-extracted with 0.2 mol· L^-1 HCl 0.2 mL. The HCl phase was evaporated to dryness with N2 stream at 80℃ - 100℃ ,and the residues were dissolved with 50 μL mobile phase. The compounds were separated on an Inertsil ODS-3 column (GL Sciences, 5 μm, 4.6 mm × 150 mm). The mobile phase was composed of aeetonitrile -50 mmol/L sodium phosphate(pH =6) (40 : 60, v/v) and vacuum filtered with 0.45 μmol/L micro filtration film. The flow rate of mobile phase was 0.6 mL · min^-1. The UV detection wave length was 210 nm. Results The relationship of the peak height ratio of reboxetine mesilate to maprotiline vs. reboxetine mesilate concentration in plasma was linear within the range of 3.12 -200 ng · mL^-1, r = 0.999 7. The lowest detection limit was 0.5 ng and the lowest concentration detected was 2 ng· mL^-1. The extraction recovery of reboxetine mesilate was 82.50% - 86.08%. The within-and between-batch preeisions were 2.02% - 5.33% and 3.83% - 8.50%, respectively. Conclusion The method is sensitive, precise, reproducible and specific, and can be used in the pharmacological research and therapeutic monitoring of reboxetine mesilate.
出处 《首都医科大学学报》 CAS 2008年第4期431-435,共5页 Journal of Capital Medical University
关键词 甲磺酸瑞波西汀 血浆浓度 高效液相色谱 紫外检测法 reboxetine mesilate plasma concentration HPLC UV detection
  • 相关文献

参考文献14

  • 1刘燕,高哲石.瑞波西汀——新型选择性去甲肾上腺素再摄取抑制剂[J].上海精神医学,2001,13(2):103-105. 被引量:14
  • 2Kadhe N G, Chillar A J, Deshmukh Y A. Reboxetine: a novel antidepressant [ J ]. J Postgrad Med, 2003,49 : 373- 375.
  • 3Delgado P L, Michaels T. Reboxitine: a review of efficacy and tolerability[ J]. Drugs of Today, 1999,35:725-737.
  • 4Tanum L. Reboxitine: tolerability and safety profile in patients with major depression [ J ]. Acta Psychiatr Scand, 2000,101 ( suppl. 402) :37-40.
  • 5Rubio G, San L, Lopez-Munoz F, et al. Reboxetine adjunct for partial or nonresponders to antidepressant treatment [ J]. J Affective Disord, 2004,81:67-72.
  • 6Edwards D M, Pellizzoni C, Breuel H P, et al. Pharmacokinetics of reboxetine in healthy volunteers: single oral doses, linearity and plasma protein binding [ J ]. Biopharm Drug Dispos, 1995,16:443-460.
  • 7Ohman D, Norlander B, Peterson C, et al. Bioanalysis of racemic reboxetine and its desethylated metabolite in a therapeutic drug monitoring setting using solid phase extraction and HPLC[ J]. Ther Drug Monit, 2001,23:27-34.
  • 8Raggi M A, Mandrioli R, Casamenti G, et al. Determination of reboxetine, a recent antidepressant drug, in human plasma by means of two high-performance liquid chromatography methods [ J ]. J Chromatogr A, 2002,949:23-33.
  • 9Frigerio F E, Pianezzola E, Strolin B M. Sensitive procedure for the determination of reboxetine enantiomers in human plasma by reversed-phase high-performance liquid chromatography with fluorimetrie detection after ehiral derivatization with ( + )-1-( 9-fluorenyl ) ethyl ehloroformate [J]. J Chromatogr A, 1994,660:351-358.
  • 10Hendershot P E, Fleishaker J C, Lin K M, et al. Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents[ J]. Psychopharmacology, 2001,155 : 148-153.

二级参考文献40

  • 1沈一峰,李华芳,马崔,陈远光,范俭雄,蓝长安,程能能,顾牛范.瑞波西汀与氟西汀治疗抑郁症随机双盲多中心临床研究[J].中国新药与临床杂志,2005,24(8):619-623. 被引量:10
  • 2李文标,周蓓蕾,张军,王智民,果伟,翟屹民,王传跃.瑞波西汀在中国男性健康志愿者体内的药动学研究[J].中国新药杂志,2005,14(9):1174-1178. 被引量:5
  • 3Fleishaker JC. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression[J]. Clin Pharmacokinet ,2000,39(6) :413 -427.
  • 4Denolle T, Pellizzoni C, Jannuzzo G, et al. Hemodynamic effects of reboxetine in healthy male volunteers [ J ]. Clin Pharmacol Ther,1999,66(3) :282 - 287.
  • 5Preskom SH. Reboxetine: a norepinephrine selective reuptake pump inhibitor[ J]. J Psychiatr Pract, 2004,10( 1 ) : 57 - 63.
  • 6Kadhe NG, Chillar AJ, Deshmukh YA. Reboxetine: a novel antidepressant [ J ] . J Postgrad Med , 2003,49 (4) : 373 - 375.
  • 7Delgado PL, Michaels T. Reboxitine: a review of efficacy and tolerability[ J]. Drugs Today, 1999,35(9) :725 - 737.
  • 8Rubio G, San L, Lopez-Munoz F, et al. Reboxetine adjunct for partial or nonresponders to antidepressant treatment [ J ]. J Affective Disord ,2004,81(1) :67 - 72.
  • 9Edwards DM, Pellizzoni C, Breuel HP, et al. Pharmacokinetics of reboxetine in healthy volunteers: single oral doses, linearity and plasma protein binding [ J ]. Biopharm Drug Dispos, 1995, 16 (6) :443 - 460.
  • 10Ohman D, Norlander B, Peterson C, et al. Bioanalysis of racemic reboxetine and its desethylated metabolite in a therapeutic drug monitoring setting using solid phase extraction and HPLC [ J ]. Ther Drug Monit ,2001,23( 1 ) :27 - 34.

共引文献15

同被引文献4

  • 1国家食品药品监督管理局.国家药品标准:YBH10432004(试行)[S].北京:中国医药科技出版社,2004.
  • 2国家食品药品监督管理局.国家药品标准:YBH02392008(试行)[S].北京:中国医药科技出版社,2008.
  • 3国家食品药品监督管理局.国家药品标准:YBH09872008[S].北京:中国医药科技出版社.2008.
  • 4梁静,李艳,罗立骏,张伟.RP-HPLC法测定甲磺酸瑞波西汀片的含量及溶出度[J].解放军药学学报,2013,29(2):146-148. 被引量:1

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部